Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: 5,17,37,5,101,... who wrote (74)	2/19/1998 7:52:00 AM
From: CPAMarty	Respond to of 2515

IMCL: IMCLONE SYSTEMS is expected to report earnings for its fiscal quarter ending 12/97 on 02/24/98. The Zacks consensus estimate of earnings per share for IMCL's 12/97 quarter is $-0.15.

To: 5,17,37,5,101,... who wrote (74)	3/4/1998 10:22:00 PM
From: CPAMarty	Respond to of 2515

Imclone<IMCL.O> sees cancer vaccine trial, Q4 loss DANA POINT, Calif, March 3 (Reuters) - ImClone Systems Inc chief operating officer Harlan Waksal said it and Merck KgaA will soon begin a Phase III multinational clinical study for its cancer vaccine BEC-2. Waksal also said he was comfortable with analysts' estimates of a $0.15 per share loss for the fourth quarter of 1997 and a full year loss of $0.61 a share for the year just ended in December. At the Cruttenden Roth Growth STock Conference, he said the study involving 600 patients will begin within a month, pending authorization from all the participating medical institutions. In a pilot study, the vaccine has shown prolonged survival of patients with small cell lung cancer. Waksal also said he hopes the company's lead product, C225, a cancer therapeutic treatment, will be in the marketplace by the end of 1999. 16:15 03-03-98 Copyright 1998 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similiar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. All active hyperlinks have been inserted by AOL.